Individual Patient Compassionate Use of Mirdametinib

Sponsor
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Study ID
NCT05028166
Status
Available

Conditions

  • Histiocytic Neoplasm
  • Neurofibromatosis Type 1-Associated Plexiform Neurofibromas
  • Other MAP-K Pathway Driven Diseases

Eligibility Criteria

Sex
ALL
Age
2 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee, and applicable competent authority approval.

Key Dates

First listed
Aug 31, 2021
Status verified
Mar 2026

Central Contacts

Related Studies